Please login to the form below
ipilimumab
This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.
Merck puts prostate cancer firmly in Keytruda’s sights
1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) in CRPC.
Latest news
-
BMS isn’t phased by Opdivo’s slowing growth – for now
ipilimumab) as a first-line treatment for non-small cell lung cancer patients with high tumour mutational burden (TMB) – an experimental biomarker that hasn’t yet been validated in a regulatory
-
AZ still sees route to approval for Imfinzi in MYSTIC trial
BMS is testing the FDA’s view on this with an application for Opdivo plus its CTLA4 inhibitor Yervoy (ipilimumab) in first-line patients with TMB above 10 mutations per megabase,
-
NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer
In the meantime, BMS will collect further data from CheckMate238, which has already shown that Opdivo improves recurrence-free survival compared to Yervoy (ipilimumab), as it aims for a routine licence.
-
Roche pulls EU Tecentriq/Avastin filing in kidney cancer
Bristol-Myers Squibb’s combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) had been turned down by the CHMP earlier this year on the grounds that adding
-
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck
More from news
Approximately 8 fully matching, plus 147 partially matching documents found.
Latest Intelligence
-
Combined immunotherapies – potential and pitfalls
This contrasts with the approved ipilimumab-nivolumab combination therapy, which costs $256, 000 a year, according to the researchers.
-
Cancer immunotherapy: What's on the horizon?
drug Yervoy (ipilimumab) in an early-stage trial.
-
Pharma deals in February 2015
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
-
Pharma deals during July 2014
Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is FDA approved for late-stage melanoma.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
CytomX appoints Rachel Humphrey chief medical officer
drug Yervoy (ipilimumab).
-
Jonathan Dickinson joins Ariad from BMS
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
Immunotherapy in oncology
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary
-
ASCO 2015: What you missed in Chicago
In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Medical Writer/ Senior Medical Writer opportunities – Macclesfie...
-
competitive salary and benefits package
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- Rising demand and understaffing puts NHS waiting times up again
- Lucid demonstrates continual investment in its central services with the appointment of its new Head of Talent, Resourcing and HR projects
- Bluebird puts €1.57m price on gene therapy Zynteglo
- Q&A with Raman Sehgal
- Hansoh Pharma shares head skyward after HKEX debut
- GSK joins forces with Doudna’s CRISPR lab
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- What are you doing, Dave?
- Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
- Fake News is Bad for your Health
- Ill informed patients make poor health decisions...
- Secrets of Pharma Advertising
- If the goal of branding is to be different, why do so many Pharma brand ads look the same?...
Quick links
Infographics
